Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide.

Published on Jan 1, 2005in Ophthalmic Surgery Lasers & Imaging0.986
路 DOI :10.3928/15428877-20050101-04
Meher Yepremyan1
Estimated H-index: 1
,
Fleming D. Wertz4
Estimated H-index: 4
+ 2 AuthorsJeffrey L. Marx10
Estimated H-index: 10
Source
Abstract
BACKGROUND AND OBJECTIVE: To determine the efficacy of intravitreal triamcinolone acetonide (IVTA) in the early treatment of severe cystoid macular edema (CME) related to acute branch retinal vein occlusion. PATIENTS AND METHODS: Retrospective, non-comparative case series. Twelve eyes with severe CME (foveal thickness > 450 microm) secondary to acute branch retinal vein occlusion received IVTA. RESULTS: Average follow-up was 15.3 months. Mean visual acuity was 0.88 LogMar units (20/160) initially, 0.55 LogMar units (20/70) at 1 week, 0.46 LogMar units (20/60) at 1 month, and 0.49 LogMar units (20/60) at last follow-up. Visual acuity improved by 3 lines or greater in 42% of patients at 1 week, 50% at 1 month, and 42% at last follow-up. Average foveal thickness was 589 microm (range, 460 to 840 microm) at baseline, 237 microm at 1 week, 196 microm at 1 month, and 235 microm at last follow-up. All eyes showed reduction of foveal thickness as measured by optical coherence tomography. Eight eyes developed recurrent CME at an average of 5.5 months after initial IVTA injection. Ten eyes required additional intervention during the follow-up period. CONCLUSIONS: Early treatment of severe CME secondary to branch retinal vein occlusion with IVTA is effective in reducing foveal thickness as measured by optical coherence tomography and improving visual acuity. However, monotherapy with IVTA can be associated with a significant rate of recurrent CME.
馃摉 Papers frequently viewed together
20053.77Eye
5 Authors (Jb Jonas, ..., Robert F. Degenring)
References19
Newest
#3Paul B Greenberg (Bascom Palmer Eye Institute)H-Index: 1
Abstract Purpose To determine if intravitreal injection of triamcinolone acetonide is safe and effective in treating diabetic macular edema unresponsive to prior laser photocoagulation. Design Prospective, noncomparative, interventional case series. Participants Sixteen eyes with clinically significant diabetic macular edema (CSME) that failed to respond to at least two previous sessions of laser photocoagulation. Methods Eyes were diagnosed with CSME and treated with at least two sessions of la...
Source
#1Paul B. GreenbergH-Index: 21
#2Adam MartidisH-Index: 14
Last. Elias ReichelH-Index: 48
view all 5 authors...
No proved treatment exists for macular oedema secondary to central retinal vein occlusion (CRVO) despite the potential for significant visual loss in affected eyes. We report a patient with bilateral non-ischaemic CRVOs and macular oedema treated with intravitreal triamcinolone acetonide. An 80 year old woman presented with a 2 week history of acute visual loss in her left eye (LE). She had a 9 month history of poor vision in her right eye (RE). On examination, visual acuity was counting fingers...
Source
#1Adam MartidisH-Index: 14
#2Jay S. DukerH-Index: 96
Last. Carmen A. PuliafitoH-Index: 94
view all 3 authors...
#1Jost B. Jonas (Heidelberg University)H-Index: 153
#2Antje S枚fker (Heidelberg University)H-Index: 7
Abstract PURPOSE: To report the clinical outcome of a diabetic patient with macular edema treated with an intravitreal injection of crystalline cortisone. METHODS: Interventional case report. A 73-year-old patient with diabetes mellitus presented with clinically significant diffuse macular edema caused by nonproliferative diabetic retinopathy. Despite grid laser coagulation in the macular region, cystoid macular edema progressed, and within 6 months before the cortisone injection, visual acuity ...
Source
#1Richard J Antcliff (St Thomas' Hospital)H-Index: 13
#2David J. Spalton (St Thomas' Hospital)H-Index: 48
Last. John Marshall (St Thomas' Hospital)H-Index: 102
view all 6 authors...
Abstract Purpose To investigate the use of intravitreal injection of triamcinolone acetonide (TA) for the treatment of refractory uveitic cystoid macular edema (CME). Design Prospective, nonrandomized, self-controlled comparative trial. Participants Six patients with chronic CME resistant to treatment with systemic steroids, orbital floor steroids, and cyclosporine A. Three patients were followed for more than 1 year, and the other three for between 3 and 9 months. Intervention Injection of 2 mg...
Source
Abstract PURPOSE: To report the clinical outcome and complications of intravitreal injections of crystalline cortisone in patients undergoing pars plana vitrectomy for treatment of proliferative diabetic retinopathy. METHODS: The prospective, interventional case series study included 29 consecutive patients (29 eyes) who underwent pars plana vitrectomy for treatment of complicated proliferative diabetic retinopathy associated with central retinal traction detachment. All patients received an int...
Source
PURPOSE. The irreversible loss of visual acuity in macular edema is usually attributed to permanent loss of photoreceptor cells, although there is hardly any information on changes in photoreceptor function in macular edema. The purpose of this study was to assess photoreceptor function in various stages of macular edema and to relate the findings to visual acuity and angiographic changes. METHODS. Directional sensitivity (optical Stiles-Crawford effect) and visual pigment density of foveal cone...
#1Ronald P. Danis (IU: Indiana University)H-Index: 62
#2Thomas A. CiullaH-Index: 57
Last. Alfredo PeceH-Index: 21
view all 6 authors...
Purpose: To examine the effects of intravitreal injection of 4.0 mg triamcinolone acetonide on the visual and clinical course of exudative age-related macular degeneration. Methods: A randomized clinical trial of a single injection of triamcinolone acetonide into the vitreous cavity of experimental eyes at baseline versus observation of untreated subjects was performed in 27 patients followed up for 6 months. Inclusion criteria included exudative age-related macular degeneration with subfoveal o...
Source
Purpose null To evaluate the efficacy of indocyanine green angiography (ICGA)-guided laser photocoagulation in eyes with fluorescein angiographic evidence of occult choroidal neovascularization (O-CNV) in patients with age-related macular degeneration (ARMD) with or without pigment epithelium detachment (PED). null Methods null Eighty eyes of 79 consecutive patients with O-CNV underwent laser treatment of a clearly outlined extrafoveal ICGA hyperfluorescent area, presumed to be focal CNV. Four t...
Source
Purpose: To ascertain whether intravitreal triamcinolone given for subretinal neovascularization is associated with an ocular pressure rise. Methods: A total of 113 patients with angiographically proven subretinal neovascularization were enrolled into a prospective study of the effects of intravitreal triamcinolone. Intraocular pressure was one of the parameters studied. Results: Approximately 30% of the study group developed a significant rise (鈮 5 mmHg) in intraocular pressure above baseline d...
Source
Cited By32
Newest
Source
#1Chang Hwan Lee (DU: Dankook University)
#2Moo Hwan Jang (DU: Dankook University)H-Index: 1
Last. Young Seung Seo (DU: Dankook University)H-Index: 2
view all 3 authors...
Source
Source
view all 4 authors...
#1Irini P. Chatziralli (QMUL: Queen Mary University of London)H-Index: 1
#2Adil Jaulim (QMUL: Queen Mary University of London)H-Index: 4
Last. Marilita M Moschos (UoA: National and Kapodistrian University of Athens)H-Index: 27
view all 5 authors...
AbstractBackground: Retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy and is considered to be an important cause of visual loss. In this review, our purpose is to update the literature about the treatment alternatives for branch retinal vein occlusion. Methods: Eligible papers were identified by a comprehensive literature search of PubMed, using the terms 鈥渂ranch retinal vein occlusion,鈥 鈥渢herapy,鈥 鈥渋ntervention,鈥 鈥渢reatment,鈥 鈥渧itrectomy,鈥 鈥渟h...
Source
Purpose: To compare clinical outcomes after intravitreal injection of triamcinolone acetonide or bevacizumab for the treatment of macular edema secondary to branch retinal vein occlusion. Methods: Sixty-six patients received an intravitreal injection of either triamcinolone acetonide or bevacizumab. Patients were retrospectively reviewed. Thirty-three out of 66 patients were treated with an intravitreal injection of triamcinolone acetonide, while the other 33 patients received a bevacizumab inje...
Source
#1Chih-Hung Kuo (RPA: Royal Prince Alfred Hospital)H-Index: 6
#2Peter McCluskey (USYD: University of Sydney)H-Index: 53
Last. Mark C Gillies (USYD: University of Sydney)H-Index: 61
view all 3 authors...
Preservative-free formulations of triamcinolone acetonide have recently been introduced to the market over concerns of local toxicity of the vehicle and preservatives, including benzyl alcohol in the original formulation, which was not designed for intraocular use. The pharmacokinetics and pharmacodynamics of intravitreal triamcinolone (IVTA) are discussed. The therapeutic effects of IVTA include improvement of visual acuity and reduction of macular edema. However, ongoing treatment is usually r...
Source
#1Wolf BuehlH-Index: 26
#2Stefan SacuH-Index: 51
Last. Ursula Schmidt-ErfurthH-Index: 92
view all 3 authors...
Retinal vein occlusion (RVO) is a common cause of vision loss in elderly people. The complex pathogenesis of central RVO (CRVO), hemi-RVO (HRVO) and branch RVO (BRVO) makes it an interdisciplinary tas
Source
#1Rainer Guthoff (University of W眉rzburg)H-Index: 12
#2Thomas MeigenH-Index: 3
Last. Wolfgang SchraderH-Index: 4
view all 4 authors...
Background: To compare the outcome of bevacizumab or triamcinolone acetate (TA) treatment in patients with macular edema (ME) after branch retinal vein occlusion (BRVO). Me
Source
#1Wolf Buehl (Medical University of Vienna)H-Index: 26
#2Ursula Schmidt-Erfurth (Medical University of Vienna)H-Index: 92
Branch retinal vein occlusion (BRVO) is a common cause for vision loss in elderly people. The complex pathogenesis of BRVO makes it an interdisciplinary task. Treatment of BRVO should aim to eliminate the complications and vision-disturbing effects of BRVO but should also include prophylactic measures in order to avoid recurrence of the disease. Problems are mainly caused by the ischemic form of BRVO, leading to neovascularization. Several treatment methods have been investigated over the past f...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.